A small molecule screen identified a lead candidate IL-8 inhibitor, NCI34255, that abrogated AML cell proliferation and restored cytarabine sensitivity in vitro via a mechanism involving Akt pathway inhibition (Vijay et al., 2019). The gene discussed is AKT1; the disease is acute myeloid leukemia.